Surveillance Strategy for Barcelona Clinic Liver Cancer B Hepatocellular Carcinoma Achieving Complete Response: An Individualized Risk-Based Machine Learning Study.
Source check: Source checked. Not independent scientific confirmation.
Finding: Full primary article reports a random-survival-forest-derived surveillance schedule for BCLC-B HCC complete responders; retrospective train/validation results reduce delayed detection, without prospective patient-benefit evidence. Organization is unavailable in the deposited bibliographic metadata.
Technology: Random survival forest for individualized surveillance timing
Publication: Publication status unspecified in annotation · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Random survival forest estimated monthly progression hazard to construct individualized surveillance timing.
- Test and result
- Full primary article reports a random-survival-forest-derived surveillance schedule for BCLC-B HCC complete responders; retrospective train/validation results reduce delayed detection, without prospective patient-benefit evidence.
- Limitation / still unknown
- The reviewed study does not establish validation or benefit beyond its reported evaluation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.3389/fbioe.2021.667641
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.